Quantitative determination of humanized monoclonal antibody rhuMAb2H7 in cynomolgus monkey serum using a Generic Immunoglobulin Pharmacokinetic (GRIP) assay

Journal of Immunological Methods

Volumn 335, Issue 1-2, 2008, Pages 8-20

  Yang, Jihong ^a   Ng, Carl ^a   Lowman, Henry ^a   Chestnut, Regina ^a   Schofield, Cheryl ^a   Sandlund, Bryan ^a   Ernst, James ^a   Bennett, Gregory ^a   Quarmby, Valerie ^a  

^a GENENTECH INC   (United States)

Author keywords

Anti CD20; Cynomolgus monkey serum; ELISA; Humanized IgG; Pharmacokinetic assay; rhuMAb2H7

Indexed keywords

BEVACIZUMAB; CD20 ANTIBODY; EFALIZUMAB; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY RHUMAB2H7; OMALIZUMAB; POLYCLONAL ANTIBODY; TRASTUZUMAB;

ACCURACY; ARTICLE; CONTROLLED STUDY; CROSS REACTION; DRUG BLOOD LEVEL; DRUG DETERMINATION; ENZYME LINKED IMMUNOSORBENT ASSAY; MONKEY; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY;

ANIMALS; ANTIBODIES; ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; ANTIGENS, CD20; ANTIRHEUMATIC AGENTS; CATTLE; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOGLOBULIN G; MACACA FASCICULARIS; REAGENT KITS, DIAGNOSTIC; RECOMBINANT PROTEINS; REPRODUCIBILITY OF RESULTS; SHEEP;

MACACA FASCICULARIS; PRIMATES;

EID: 43049158163     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jim.2008.01.016     Document Type: Article

References (45)

1. Anolik J., Sanz I., and Looney R.J. B cell depletion therapy in systemic lupus erythematosus. Curr. Rheumatol. Rep. 5 (2003) 350
2. Anonymous. IFCC provisional recommendation on quality control in clinical chemistry. J. Clin. Chem. Biochem. 14 (1976) 270
3. Biagini R.E., Moorman W.J., Lal J.B., Gallagher J.S., and Bernstein I.L. Normal serum IgE and IgG antibody levels in adult male cynomolgus monkeys. Lab. Anim. Sci. 38 (1988) 194
4. Boon L., Laman J.D., Ortiz-Buijsse A., den Hartog M.T., Hoffenberg S., Liu P., Shiau F., and de Boer M. Preclinical assessment of anti-CD40 Mab 5D12 in cynomolgus monkeys. Toxicology 174 (2002) 53
5. Clark E.A., and Ledbetter J.A. Structure, function, and genetics of human B cell-associated surface molecules. Adv. Cancer Res. 52 (1989) 81
6. Clark E.A., Shu G., and Ledbetter J.A. Role of the Bp35 cell surface polypeptide in human activation. Proc. Natl. Acad. Sci. U. S. A. 82 (1985) 1766
7. Corcione A., Aloisi F., Serafini B., Capello E., Mancardi G.L., Pistoia V., and Uccelli A. B-cell differentiation in the CNS of patients with multiple sclerosis. Autoimmun. Rev. 4 (2005) 549
8. D'Ovidio M.C., Pace M., Via F., Strom R., and Turillazzi P.G. Characterization of kappa and lambda light immunoglobulin chains in adult macaca fascicularis. Folia Primatol. 63 (1994) 221
9. Da Silva M., Petruzzo P., Virieux S., Tiollier J., Badet L., and Martin X. A primate model of renal ischemia-reperfusion injury for preclinical evaluation of the antileukocyte function associated antigen 1 monoclonal antibody odulimonab. J. Urol. 166 (2001) 1915
10. DeSilva B., Smith W., Weiner R., Kelley M., Smolec J., Lee B., Khan M., Tacey R., Hill H., and Celniker A. Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules. Pharm. Res. 20 (2003) 1885
11. Dodds M.G., Visich J.E., and Vicini P. Population pharmacokinetics of recombinant factor XIII in cynomolgus monkeys. AAPS J. 7 (2005) E693
12. Dorner T., and Burmester G.R. The role of B cells in rheumatoid arthritis: mechanisms and therapeutic targets. Curr. Opin. Rheumatol. 15 (2003) 246
13. Dubois D.Y., Cantraine F., and Malmendier C.L. Comparison of different sandwich enzyme immunoassays for the quantitation of human apolipoproteins A-I and A-II. J. Immunol. Methods 96 (1987) 115
14. Gopal A.K., and Press O.W. Clinical applications of anti-CD20 antibodies. J. Lab. Clin. Med. 134 (1999) 445
15. Harlow E., and Lane D. Antibodies, a Laboratory Manual (1988), Cold Spring Harbor Press, NY
16. Hart T.K., Cook R.M., Zia-Amirhosseini P., Minthorn E., Sellers T.S., Maleeff B.E., Eustis S., Schwartz L.W., Tsui P., Appelbaum E.R., Martin E.C., Bugelski P.J., and Herzyk D.J. Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys. J. Allergy Clin. Immunol. 108 (2001) 250
17. Hashida S., Nakagawa K., Imagawa M., Inoue S., Yoshitake S., Ishikawa E., Endo Y., Ohtaki S., Ichioka Y., and Nakajima K. Use of inorganic salts to minimize serum interference in a sandwich enzyme immunoassay for human growth hormone using Fab'-horseradish peroxidase conjugate. Clin. Chim. Acta 135 (1983) 263
18. Hong K., Presta L.G., Lu Y., Penn A., Adams C., Chuntharapai A., Yang J., Wong W.L., and Meng Y.G. Simple quantitative live cell and anti-idiotypic antibody based ELISA for humanized antibody directed to cell surface protein CD20. J. Immunol. Methods 294 (2004) 189
19. Isenberg D.A. B cell targeted therapies in autoimmune diseases. J. Rheumatol., Suppl. 77 (2006) 24
20. Jensen M., Winkler U., Manzke O., Diehl V., and Engert A. Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab). Ann. Hematol. 77 (1998) 89
21. Kapyaho K., Tanner P., and Weber T. Effect of complement binding on a solid-phase immunometric TSH assay. Scand. J. Clin. Lab. Invest. 49 (1989) 211
22. Kelley S.K., Harris L.A., Xie D., Deforge L., Totpal K., Bussiere J., and Fox J.A. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J. Pharmacol. Exp. Ther. 299 (2001) 31
23. Keystone E. B cell targeted therapies. Arthritis Res. Ther. 7 Suppl 3 (2005) S13
24. Kosmas C., Stamatopoulos K., Stavroyianni N., Tsavaris N., and Papadaki T. Anti-CD20-based therapy of B cell lymphoma: state of the art. Leukemia 16 (2002) 2004
25. Krummen L.A., Woodruff T.K., DeGuzman G., Cox E.T., Baly D.L., Mann E., Garg S., Wong W.L., Cossum P., and Mather J.P. Identification and characterization of binding proteins for inhibin and activin in human serum and follicular fluids. Endocrinology 132 (1993) 431
26. Levinson S.S., and Miller J.J. Towards a better understanding of heterophile (and the like) antibody interference with modern immunoassays. Clin. Chim. Acta 325 (2002) 1
27. Lewis A.P., Barber K.A., Cooper H.J., Sims M.J., Worden J., and Crowe J.S. Cloning and sequence analysis of kappa and gamma cynomolgus monkey immunoglobulin cDNAs. Dev. Comp. Immunol. 17 (1993) 549
28. Looney R.J. Treating human autoimmune disease by depleting B cells. Ann. Rheum. Dis. 61 (2002) 863
29. McLaughlin P., White C.A., Grillo-Lopez A.J., and Maloney D.G. Clinical status and optimal use of rituximab for B-cell lymphomas. Oncology (Williston Park) 12 (1998) 1763 discussion 1769-70, 1775-7
30. Moore J., Ma D., Will R., Cannell P., Handel M., and Milliken S. A phase II study of Rituximab in rheumatoid arthritis patients with recurrent disease following haematopoietic stem cell transplantation. Bone Marrow Transplant. 34 (2004) 241
31. Oligino T.J., and Dalrymple S.A. Targeting B cells for the treatment of rheumatoid arthritis. Arthritis Res. Ther. 5 Suppl 4 (2003) S7
32. Pace M., D'Ovidio M.C., Iale E., Strom R., and Turillazzi P. Serum kappa and lambda light immunoglobulin chains in cynomolgus macaques (Macaca fascicularis) during the first twenty months of age. Immunol. Lett. 50 (1996) 139
33. Panayi G.S. B cell-directed therapy in rheumatoid arthritis-clinical experience. J. Rheumatol., Suppl. 73 (2005) 19 discussion 29-30
34. Ponce R., Armstrong K., Andrews K., Hensler J., Waggie K., Heffernan J., Reynolds T., and Rogge M. Safety of recombinant human factor XIII in a cynomolgus monkey model of extracorporeal blood circulation. Toxicol. Pathol. 33 (2005) 702
35. Pruslin F.H., To S.E., Winston R., and Rodman T.C. Caveats and suggestions for the ELISA. J. Immunol. Methods 137 (1991) 27
36. Riley J.K., and Sliwkowski M.X. CD20: a gene in search of a function. Semin. Oncol. 27 (2000) 17
37. Selby C. Interference in immunoassay. Ann. Clin. Biochem. 36 Pt 6 (1999) 704
38. Shaw T., Quan J., and Totoritis M.C. B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience. Ann. Rheum. Dis. 62 Suppl 2 (2003) ii55
39. Stashenko P., Nadler L.M., Hardy R., and Schlossman S.F. Characterization of a human B lymphocyte-specific antigen. J. Immunol. 125 (1980) 1678
40. Tedder T.F., and Engel P. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol. Today 15 (1994) 450
41. Tedder T.F., and Schlossman S.F. Phosphorylation of the B1 (CD20) molecule by normal and malignant human B lymphocytes. J. Biol. Chem. 263 (1988) 10009
42. Tryphonas H., Karpinski K., O'Grady L., and Hayward S. Quantitation of serum immunoglobulins G, M, and A in the rhesus monkey (M. mulatta) using human monospecific antisera in the enzyme-linked immunosorbent assay: developmental aspects. J. Med. Primatol. 20 (1991) 58
43. Tuscano J.M., Martin S., Song K., and Wun T. B cell reductive therapy in the treatment of autoimmune diseases: a focus on monoclonal antibody treatment of rheumatoid arthritis. Hematology 10 (2005) 521
44. von Schilling C. Immunotherapy with anti-CD20 compounds. Semin. Cancer Biol. 13 (2003) 211
45. Vugmeyster Y., Beyer J., Howell K., Combs D., Fielder P., Yang J., Qureshi F., Sandlund B., Kawaguchi L., Dummer W., Lowman H., and McKeever K. Depletion of B cells by a humanized anti-CD20 antibody PRO70769 in Macaca fascicularis. J. Immunother. 28 (2005) 212